Qurient Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Public

  • Employees
  • 32

Employees

  • Stock Symbol
  • 115180

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $10.87
  • (As of Friday Closing)

Qurient General Information

Description

Qurient Co Ltd is a South Korea based biotech company. It is engaged in network research & development business model, integrating research and drug development programs with a new mechanism. Its pipeline products include Q301 for the treatment of atopic dermatitis; Q203 treats MDR/XDR/TDR TB, and Q701 is a drug-resistant cancer immuno-oncology.

Contact Information

Website
www.qurient.com
Formerly Known As
Quro Science
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • C-dong 801, 242, Pangyo-ro
  • Bundang-gu
  • Seongnam, Gyeonggi 13487
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
KRX
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • C-dong 801, 242, Pangyo-ro
  • Bundang-gu
  • Seongnam, Gyeonggi 13487
  • South Korea
+82

Qurient Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Qurient Stock Performance

As of 13-Nov-2026, Qurient’s stock price is $10.87. Its current market cap is $413M with 38M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$10.87 $12.30 $9.37 - $40.59 $413M 38M 181K -$0.69

Qurient Financials Summary

As of 30-Sep-2026, Qurient has a trailing 12-month revenue of $4.88M.

In Thousands,
USD 		TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 598,192 709,476 65,581 85,849
Revenue 4,884 4,907 6,728 6,908
EBITDA (26,860) (21,856) (18,753) (16,761)
Net Income (26,522) (21,118) (17,671) (16,151)
Total Assets 29,102 43,051 39,424 38,614
Total Debt 10,914 8,786 571 259
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Qurient Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Qurient‘s full profile, request access.

Request a free trial

Qurient Patents

  • 130

    Total Documents Applications and Grants

  • Total Patents Families

  • 73

    Granted

  • 30

    Pending

  • Expiring in next 12 mo

Qurient Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026224352-A1 Quinoline derivatives for use in the treatment of an immunological disease or dysfunction, in particular of chronic graft-versus-host-disease (cgvhd) Pending 24-Apr-2025
AU-2023317788-A1 Combination therapy of cdk7 inhibitors with other anti-cancer therapies Pending 05-Aug-2022
EP-4565239-A1 Combination therapy of cdk7 inhibitors with other anti-cancer therapies Pending 05-Aug-2022
US-20260041693-A1 Combination therapy of cdk7 inhibitors with other anti-cancer therapies Pending 05-Aug-2022
WO-2024028411-A1 Combination therapy of cdk7 inhibitors with other anti-cancer therapies Inactive 05-Aug-2022 A61K31/53
To view Qurient’s complete patent history, request access »

Qurient Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Qurient Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Qurient‘s full profile, request access.

Request a free trial

Qurient Investments (2)

Qurient’s most recent deal was a Later Stage VC with QLi5 Therapeutics for . The deal was made on 27-Jan-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
QLi5 Therapeutics 27-Jan-2026 Later Stage VC Drug Discovery
QLi5 Therapeutics 16-Jan-2020 Joint Venture Drug Discovery
To view Qurient’s complete investments history, request access »

Qurient ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Qurient’s complete esg history, request access »

Qurient FAQs

  • When was Qurient founded?

    Qurient was founded in 2008.

  • Where is Qurient headquartered?

    Qurient is headquartered in Seongnam, South Korea.

  • What is the size of Qurient?

    Qurient has 32 total employees.

  • What industry is Qurient in?

    Qurient’s primary industry is Drug Discovery.

  • Is Qurient a private or public company?

    Qurient is a Public company.

  • What is Qurient’s stock symbol?

    The ticker symbol for Qurient is 115180.

  • What is the current stock price of Qurient?

    As of 13-Nov-2026 the stock price of Qurient is $10.87.

  • What is the current market cap of Qurient?

    The current market capitalization of Qurient is $413M.

  • What is Qurient’s current revenue?

    The trailing twelve month revenue for Qurient is $4.88M.

  • What is Qurient’s annual earnings per share (EPS)?

    Qurient’s EPS for 12 months was -$0.69.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process